116 related articles for article (PubMed ID: 34845574)
1. Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?
Garbez N; Mbatchi LC; Louart G; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
Pharm Res; 2021 Nov; 38(11):1863-1871. PubMed ID: 34845574
[TBL] [Abstract][Full Text] [Related]
2. Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections.
Garbez N; Mbatchi L; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230720. PubMed ID: 33846133
[TBL] [Abstract][Full Text] [Related]
3. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.
Chandra S; Fukuda T; Mizuno K; Davies SM; Teusink-Cross A; Tarin R; Marsh RA; Vinks AA; Mehta PA
J Antimicrob Chemother; 2018 Jun; 73(6):1651-1658. PubMed ID: 29481593
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis.
Zhong S; Zhu X; Zhao L; Song Y; Yu J; Zheng Z; Zang B
Pharm Res; 2021 Jan; 38(1):67-77. PubMed ID: 33404989
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?
Kapralos I; Mainas E; Neroutsos E; Apostolidi S; Siopi M; Apostolopoulou O; Dimopoulos G; Sambatakou H; Valsami G; Meletiadis J; Dokoumetzidis A
J Pharm Pharmacol; 2020 Dec; 72(12):1750-1760. PubMed ID: 32789881
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.
Leroux S; Jacqz-Aigrain E; Elie V; Legrand F; Barin-Le Guellec C; Aurich B; Biran V; Dusang B; Goudjil S; Coopman S; Garcia Sanchez R; Zhao W; Manzoni P;
Br J Clin Pharmacol; 2018 Sep; 84(9):1989-1999. PubMed ID: 29744900
[TBL] [Abstract][Full Text] [Related]
7. Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.
Kovanda LL; Walsh TJ; Benjamin DK; Arrieta A; Kaufman DA; Smith PB; Manzoni P; Desai AV; Kaibara A; Bonate PL; Hope WW
Pediatr Infect Dis J; 2018 Jun; 37(6):580-585. PubMed ID: 29762386
[TBL] [Abstract][Full Text] [Related]
8. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
Grau S; Luque S; Campillo N; Samsó E; Rodríguez U; García-Bernedo CA; Salas E; Sharma R; Hope WW; Roberts JA
J Antimicrob Chemother; 2015 Oct; 70(10):2854-61. PubMed ID: 26180134
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
10. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
García-de-Lorenzo A; Luque S; Grau S; Agrifoglio A; Cachafeiro L; Herrero E; Asensio MJ; Sánchez SM; Roberts JA
Antimicrob Agents Chemother; 2016 Oct; 60(10):5914-21. PubMed ID: 27458229
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.
Wasmann RE; Muilwijk EW; Burger DM; Verweij PE; Knibbe CA; Brüggemann RJ
Clin Pharmacokinet; 2018 Mar; 57(3):267-286. PubMed ID: 28791666
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study.
Garbez N; Mbatchi LC; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
Clin Pharmacokinet; 2022 May; 61(5):673-686. PubMed ID: 34931282
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults.
Wasmann RE; Smit C; Ter Heine R; Koele SE; van Dongen EPH; Wiezer RMJ; Burger DM; Knibbe CAJ; Brüggemann RJM
J Antimicrob Chemother; 2019 Apr; 74(4):978-985. PubMed ID: 30649375
[TBL] [Abstract][Full Text] [Related]
15. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Zijlstra JG; van der Werf TS; Alffenaar JWC; Touw DJ
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0111322. PubMed ID: 36377940
[No Abstract] [Full Text] [Related]
17. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study.
López-Sánchez M; Moreno-Puigdollers I; Rubio-López MI; Zarragoikoetxea-Jauregui I; Vicente-Guillén R; Argente-Navarro MP
Rev Bras Ter Intensiva; 2020 Jun; 32(2):277-283. PubMed ID: 32667449
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
Hope WW; Seibel NL; Schwartz CL; Arrieta A; Flynn P; Shad A; Albano E; Keirns JJ; Buell DN; Gumbo T; Drusano GL; Walsh TJ
Antimicrob Agents Chemother; 2007 Oct; 51(10):3714-9. PubMed ID: 17638696
[TBL] [Abstract][Full Text] [Related]
20. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
